{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T19:40:03Z","timestamp":1729971603996,"version":"3.28.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Osteoporosis has been recognized as a significant health issue in Thailand. Pharmacological interventions are important way to prevent fracture. However, one of the main challenges in selecting a medication is high cost, particularly for brand-name drugs. Data on generic bisphosphonate use in Thai are still lacking. Therefore, our study aimed to assess the efficacy and safety of generic risedronate in postmenopausal Thai women with osteoporosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, from December 2022 to January 2024. Serum C-terminal cross-linking telopeptide of type I collagen (CTX) and procollagen type I N-propeptide (P1NP) were measured at baseline. All participants subsequently received 35 milligrams of oral risedronate once weekly for 52 weeks. Serum CTX and P1NP were remeasured at different time points. BMD was reevaluated at 52 weeks after risedronate treatment initiation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 80 participants were included. The mean age was 65.2\u2009\u00b1\u20096.6 years. The mean body mass index (BMI) was 23.45\u2009\u00b1\u20093.49\u00a0kg\/m<jats:sup>2<\/jats:sup>. The median (IQR) serum CTX level at 12 weeks was significantly lower than that at baseline (0.28 (0.16\u20130.46) ng\/mL versus 0.44 (0.26\u20130.64) ng\/mL, respectively; p value\u2009&lt;\u20090.01). The suppression of serum CTX was confirmed at 52 weeks after treatment initiation. Compared with those at baseline, the serum P1NP levels were significantly lower at 24 weeks after treatment initiation (30.33 (19.19\u201339.58) ng\/mL versus 41.90 (30.33\u201368.67) ng\/mL, respectively; p value\u2009&lt;\u20090.01). In terms of the BMD assessment at 52 weeks, significant improvements were observed in both areal BMD (g\/cm<jats:sup>2<\/jats:sup>) and T scores at all measured sites compared with baseline. The lumbar spine, femoral neck, and total hip BMD increased from baseline by 4.76%, 3.84% and 4.54%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Postmenopausal women with osteoporosis who were treated with generic risedronate demonstrated significant suppression of the bone remodelling process at 3, 6, and 12 months after treatment initiation. Additionally, significant improvements in the lumbar spine, femoral neck, and total hip BMD were observed at 12 months of therapy. These findings suggest that generic risedronate could be considered a reasonable and interesting option for treating postmenopausal women with osteoporosis in Thailand.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-024-03404-5","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T07:01:43Z","timestamp":1729926103000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes of bone turnover markers and bone mineral density among postmenopausal Thai women with osteoporosis receiving generic risedronate"],"prefix":"10.1186","volume":"24","author":[{"given":"Ammarin","family":"Suwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chotetawan","family":"Tanavalee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krasean","family":"Panyakhamlerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srihatach","family":"Ngarmukos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchanant","family":"Chavaengkiat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aree","family":"Tanavalee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chavarin","family":"Amarase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanapob","family":"Bumphenkiatikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"3404_CR1","doi-asserted-by":"publisher","first-page":"e0279829","DOI":"10.1371\/journal.pone.0279829","volume":"18","author":"P Chanidkul","year":"2023","unstructured":"Chanidkul P, Sribenjalak D, Charoenngam N, Pongchaiyakul C. The proportion of Thai postmenopausal women who would be eligible for anti-osteoporosis therapy. PLoS ONE. 2023;18:e0279829.","journal-title":"PLoS ONE"},{"key":"3404_CR2","first-page":"261","volume":"91","author":"C Pongchaiyakul","year":"2008","unstructured":"Pongchaiyakul C, Songpattanasilp T, Taechakraichana N. Burden of osteoporosis in Thailand. J Med Assoc Thai. 2008;91:261\u20137.","journal-title":"J Med Assoc Thai"},{"key":"3404_CR3","first-page":"725","volume":"83","author":"KK Limpaphayom","year":"2000","unstructured":"Limpaphayom KK, Taechakraichana N, Jaisamrarn U, Bunyavejchevin S, Chaikittisilpa S, Poshyachinda M, Taechamahachai C, Havanond P, Onthuam Y, Lumbiganon P, Kamolratanakul P. Bone mineral density of lumbar spine and proximal femur in normal Thai women. J Med Assoc Thai. 2000;83:725\u201331.","journal-title":"J Med Assoc Thai"},{"key":"3404_CR4","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R. National osteoporosis F: Clinician\u2019s guide to Prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359\u201381.","journal-title":"Osteoporos Int"},{"key":"3404_CR5","first-page":"427","volume":"34","author":"P Suriyawongpaisal","year":"2003","unstructured":"Suriyawongpaisal P, Chariyalertsak S, Wanvarie S. Quality of life and functional status of patients with hip fractures in Thailand. Southeast Asian J Trop Med Public Health. 2003;34:427\u201332.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"3404_CR6","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00198-023-06822-7","volume":"34","author":"EJ Yeh","year":"2023","unstructured":"Yeh EJ, Rajkovic-Hooley O, Silvey M, Ambler WS, Milligan G, Pinedo-Villanueva R, Harvey NC, Moayyeri A. Impact of fragility fractures on activities of daily living and productivity in community-dwelling women: a multi-national study. Osteoporos Int. 2023;34:1751\u201362.","journal-title":"Osteoporos Int"},{"key":"3404_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocd.2009.10.003","volume":"13","author":"T Vaseenon","year":"2010","unstructured":"Vaseenon T, Luevitoonvechkij S, Wongtriratanachai P, Rojanasthien S. Long-term mortality after osteoporotic hip fracture in Chiang Mai, Thailand. J Clin Densitom. 2010;13:63\u20137.","journal-title":"J Clin Densitom"},{"key":"3404_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13018-019-1226-6","volume":"14","author":"O Guzon-Illescas","year":"2019","unstructured":"Guzon-Illescas O, Perez Fernandez E, Crespi Villarias N, Quiros Donate FJ, Pena M, Alonso-Blas C, Garcia-Vadillo A, Mazzucchelli R. Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. J Orthop Surg Res. 2019;14:203.","journal-title":"J Orthop Surg Res"},{"key":"3404_CR9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33:2049\u2013102.","journal-title":"Osteoporos Int"},{"key":"3404_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4:368\u201381.","journal-title":"Osteoporos Int"},{"key":"3404_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrrheum.2012.86","volume":"8","author":"K Naylor","year":"2012","unstructured":"Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol. 2012;8:379\u201389.","journal-title":"Nat Rev Rheumatol"},{"key":"3404_CR12","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","volume":"5","author":"R Eastell","year":"2017","unstructured":"Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5:908\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3404_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/endrev\/bnac031","volume":"44","author":"M Schini","year":"2023","unstructured":"Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone turnover markers: Basic Biology to Clinical Applications. Endocr Rev. 2023;44:417\u201373.","journal-title":"Endocr Rev"},{"key":"3404_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","volume":"8","author":"B Langdahl","year":"2016","unstructured":"Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2016;8:225\u201335.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3404_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","volume":"49","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, Kanis JA. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011;49:1271\u20134.","journal-title":"Clin Chem Lab Med"},{"issue":"Suppl 6","key":"3404_CR16","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1007\/s001980070002","volume":"11","author":"PD Delmas","year":"2000","unstructured":"Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J, Committee of Scientific Advisors of the International Osteoporosis F. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11(Suppl 6):S2\u201317.","journal-title":"Osteoporos Int"},{"key":"3404_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","volume":"19","author":"NB Watts","year":"2008","unstructured":"Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19:365\u201372.","journal-title":"Osteoporos Int"},{"key":"3404_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jocd.2019.03.004","volume":"24","author":"CH Wu","year":"2021","unstructured":"Wu CH, Chang YF, Chen CH, Lewiecki EM, Wuster C, Reid I, Tsai KS, Matsumoto T, Mercado-Asis LB, Chan DC, et al. Consensus Statement on the use of bone turnover markers for short-term monitoring of osteoporosis treatment in the Asia-Pacific Region. J Clin Densitom. 2021;24:3\u201313.","journal-title":"J Clin Densitom"},{"key":"3404_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, et al. American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal Osteoporosis-2020 Update. Endocr Pract. 2020;26:1\u201346.","journal-title":"Endocr Pract"},{"key":"3404_CR20","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032\u201345.","journal-title":"Mayo Clin Proc"},{"key":"3404_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.afos.2015.09.003","volume":"1","author":"A Suwan","year":"2015","unstructured":"Suwan A, Panyakhamlerd K, Chaikittisilpa S, Jaisamrarn U, Hawanond P, Chaiwatanarat T, Tepmongkol S, Chansue E, Taechakraichana N. Validation of the Thai osteoporosis foundation and royal college of orthopaedic surgeons of Thailand clinical practice guideline for bone mineral density measurement in postmenopausal women. Osteoporos Sarcopenia. 2015;1:103\u20138.","journal-title":"Osteoporos Sarcopenia"},{"key":"3404_CR22","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/jbmr.3757","volume":"34","author":"Q Zeng","year":"2019","unstructured":"Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q, Huang J, Wen Q, Hu R, Wang L, et al. The prevalence of osteoporosis in China, a Nationwide, Multicenter DXA Survey. J Bone Min Res. 2019;34:1789\u201397.","journal-title":"J Bone Min Res"},{"key":"3404_CR23","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jval.2011.11.015","volume":"15","author":"P Kingkaew","year":"2012","unstructured":"Kingkaew P, Maleewong U, Ngarmukos C, Teerawattananon Y. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis. Value Health. 2012;15:S20\u201328.","journal-title":"Value Health"},{"key":"3404_CR24","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555\u201365.","journal-title":"J Clin Endocrinol Metab"},{"key":"3404_CR25","first-page":"CD004523","volume":"5","author":"GA Wells","year":"2022","unstructured":"Wells GA, Hsieh SC, Zheng C, Peterson J, Tugwell P, Liu W. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2022;5:CD004523.","journal-title":"Cochrane Database Syst Rev"},{"key":"3404_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.11005\/jbm.2013.20.1.31","volume":"20","author":"SY Kong","year":"2013","unstructured":"Kong SY, Kim DY, Han EJ, Park SY, Yim CH, Kim SH, Yoon HK. Effects of a \u2018drug holiday\u2019 on bone mineral density and bone turnover marker during bisphosphonate therapy. J Bone Metab. 2013;20:31\u20135.","journal-title":"J Bone Metab"},{"key":"3404_CR27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4158\/EP171781.OR","volume":"23","author":"Y Liel","year":"2017","unstructured":"Liel Y, Plakht Y, Tailakh MA, BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT. IMPLICATIONS FOR TREATMENT FAILURE AND DRUG HOLIDAY IN THE REAL WORLD. Endocr Pract. 2017;23:787\u201393.","journal-title":"Endocr Pract"},{"key":"3404_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","volume":"19","author":"RJ Baber","year":"2016","unstructured":"Baber RJ, Panay N, Fenton A, Group IMSW. 2016 IMS recommendations on women\u2019s midlife health and menopause hormone therapy. Climacteric. 2016;19:109\u201350.","journal-title":"Climacteric"},{"key":"3404_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12905-021-01508-w","volume":"21","author":"J Vatrasresth","year":"2021","unstructured":"Vatrasresth J, Suwan A, Panyakhamlerd K. Effects of early estradiol valerate administration on bone turnover markers in surgically induced menopausal women. BMC Womens Health. 2021;21:363.","journal-title":"BMC Womens Health"},{"key":"3404_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2165\/00003495-200161050-00013","volume":"61","author":"CJ Dunn","year":"2001","unstructured":"Dunn CJ, Goa KL. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs. 2001;61:685\u2013712.","journal-title":"Drugs"},{"key":"3404_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.eprac.2021.02.001","volume":"27","author":"NB Watts","year":"2021","unstructured":"Watts NB, Camacho PM, Lewiecki EM, Petak SM, Force AAPOGT. American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal Osteoporosis-2020 Update. Endocr Pract. 2021;27:379\u201380.","journal-title":"Endocr Pract"},{"key":"3404_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4065\/77.3.262","volume":"77","author":"H Taggart","year":"2002","unstructured":"Taggart H, Bolognese MA, Lindsay R, Ettinger MP, Mulder H, Josse RG, Roberts A, Zippel H, Adami S, Ernst TF, Stevens KP. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc. 2002;77:262\u201370.","journal-title":"Mayo Clin Proc"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-03404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-024-03404-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-03404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T19:02:30Z","timestamp":1729969350000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-024-03404-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3404"],"URL":"https:\/\/doi.org\/10.1186\/s12905-024-03404-5","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institution Review Board of the Faculty of Medicine, Chulalongkorn University (IRB 115\/61). Written informed consent was obtained from all participants prior to the start of the study. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"572"}}